N-Acetyl Epithalon Amidate
A terminally capped variant of Epithalon with zero publications of its own — six phrase searches return nothing, and the FDA's own exhaustive 2026 literature review never encountered it. The parent peptide now has one independent telomerase replication, from Brunel University London, which also found telomere lengthening in breast cancer cells via ALT activation.
This is Epitalon with chemical caps on both ends, meant to make it last longer in the body. No study of the capped version has ever been published — not one, anywhere. The parent peptide does lengthen telomeres in cells, confirmed independently in 2025, and that same study found it lengthened telomeres in breast cancer cells too, by a route specific to cancer.
What is N-Acetyl Epithalon Amidate?
N-Acetyl Epithalon Amidate is a modified version of Epithalon (epitalon), the synthetic tetrapeptide Ala-Glu-Asp-Gly, with N-acetyl and C-amide terminal modifications that improve enzymatic stability and potentially enhance bioavailability. Epithalon was designed by Professor Vladimir Khavinson's research group from the amino-acid composition of epithalamin, a bovine pineal polypeptide extract rather than a single peptide. It is studied for its ability to activate telomerase, regulate melatonin synthesis, stimulate neurogenesis, and potentially slow cellular aging.
What N-Acetyl Epithalon Amidate Is Investigated For
N-Acetyl Epithalon Amidate is a stability-modified analogue of Epithalon marketed for telomerase activation, pineal-axis and melatonin-rhythm support, neuroprotection, and general longevity and anti-aging use. The strongest (and still modest) evidence sits with the parent compound Epithalon — in vitro telomerase upregulation, rodent lifespan-extension findings, and a small retinitis pigmentosa clinical study — not with the amidate variant, which has no independent preclinical or human trial program of its own. A 2026 Frontiers in Aging review continues to position epitalon primarily as a telomere-biology agent within the broader gerontological peptide landscape, while flagging the absence of long-term human safety data. Claims that the N-acetyl and C-amide modifications produce a superior or longer-lasting effect rest on peptide-chemistry reasoning about peptidase resistance rather than on head-to-head pharmacokinetic or clinical data. That single-lineage concern is no longer absolute, and the update cuts both ways. In 2025 a group at Brunel University London — no Khavinson involvement, no declared competing interests — reported dose-dependent telomere lengthening in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation, the first genuinely independent replication in the 22 years since the original claim. The same study found telomere lengthening in breast cancer lines through alternative lengthening of telomeres activation, which the authors reported was specific to the cancer cells. Note also that the paper carries a published correction replacing the figures in its telomere, hTERT and telomerase panels. The FDA, reviewing this literature in 2026, independently reached the same conclusion about its provenance: 'Most pharmacological studies of epitalon have been conducted and published by Dr. Khavinson's research group in Russia.' The honest framing: extrapolation from Epithalon plus chemistry intuition, with essentially no direct evidence for the amidate form in humans.
History & Discovery
N-Acetyl Epithalon Amidate is a stability-modified analogue of Epithalon, the original Khavinson tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s. The base sequence (Ala-Glu-Asp-Gly) was synthesized by Vladimir Khavinson and colleagues from the amino-acid composition of epithalamin, a crude pineal extract their group had studied since the 1970s — it was not isolated from the extract as an active fragment, and a 2026 review warns that the two should not be treated interchangeably. The N-acetyl and C-amide modifications are not from a separate discovery program but rather a structural strategy borrowed from broader peptide-chemistry practice — N-terminal acetylation blocks aminopeptidase cleavage and C-terminal amidation blocks carboxypeptidase cleavage, both intended to extend half-life in plasma and tissue. There is no independent published preclinical or clinical program for the amidate variant comparable to the body of work on plain Epithalon. The variant exists primarily as a research-chemical market offering, marketed on the assumption that the modifications enhance potency or duration without changing the underlying mechanism. That assumption has not been validated by head-to-head pharmacokinetic or pharmacodynamic comparison in humans, and the entire Epithalon literature already concentrates in a single research lineage.
How It Works
This is a more stable version of Epithalon that may activate telomerase more effectively. Telomerase rebuilds the protective caps (telomeres) on your chromosomes that shorten with age, potentially slowing cellular aging. It also supports pineal gland function and melatonin production, which decline with age.
Like Epithalon, N-Acetyl Epithalon Amidate is proposed to activate telomerase through upregulation of hTERT (human telomerase reverse transcriptase) gene expression. The N-acetylation protects against aminopeptidase degradation while the C-terminal amidation prevents carboxypeptidase degradation, potentially increasing circulating half-life and tissue exposure. The core tetrapeptide sequence (Ala-Glu-Asp-Gly) has been identified within the polypeptide complex of the pineal gland and interacts with DNA regulatory regions to modulate gene expression via epigenetic mechanisms. Research demonstrates it stimulates neurogenesis-related gene expression and protein synthesis, regulates melatonin synthesis in pinealocytes through signaling molecule modulation, and influences proliferative activity and inflammatory pathways in immune cells.
Evidence Snapshot
Human Clinical Evidence
Limited. One controlled clinical trial showed improvement in retinitis pigmentosa patients. Melatonin rhythm normalization studied in elderly subjects. Most data from Russian research groups.
Animal / Preclinical
Moderate for Epithalon. Studies in mice show lifespan extension and reduced tumor incidence. Oocyte protection from aging-related damage demonstrated. Pineal and pancreatic hormone restoration in aged primates.
Mechanistic Rationale
Moderate for the parent in cell culture, speculative for the variant. Telomerase activation and telomere elongation are now confirmed in human cell lines by an independent group as well as the originating one — but in vitro only, with no human in vivo demonstration, and the independent paper required a figure correction. The melatonin claim deserves more caution than it usually gets: a study co-authored by Khavinson and Anisimov themselves found AEDG had no significant effect on melatonin secretion from perifused rat pineal glands at any age, and did not modify isoproterenol-stimulated melatonin either. Nothing at all has been demonstrated for the acetylated amidated form.
Research Gaps & Open Questions
What the current literature has not yet settled about N-Acetyl Epithalon Amidate:
- 01Independent comparison of the amidate variant vs. plain Epithalon — no published head-to-head pharmacokinetic or efficacy study confirms that the chemical modifications translate to clinical superiority.
- 02Independent replication outside the Khavinson research program — efficacy claims for the parent Epithalon trace back to a single research group, and the amidate variant has even less independent verification.
- 03Pharmacokinetics in humans — absorption, distribution, half-life, and clearance are uncharacterized; the assumed half-life advantage from N-acetyl and C-amide modifications is theoretical.
- 04Long-term cancer safety — given the telomerase-activation mechanism, pharmacovigilance for malignancy outcomes is a critical and unaddressed gap.
- 05Blinded randomized controlled trials in humans for any longevity or anti-aging endpoint.
- 06Mechanism specificity — whether a tetrapeptide actually activates telomerase expression in vivo at claimed doses, and the specificity of that effect, has not been independently confirmed.
Forms & Administration
Subcutaneous injection. Dosing protocols similar to Epithalon. Often used in 10-20 day cycles. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Forum-described protocols mirror Epithalon: 5–10 mg per dose subcutaneously, sometimes lower (1–3 mg) on the assumption that improved stability allows reduced dosing. None of these numbers come from a published dose-finding study of the amidate variant specifically.
Frequency
Daily SC injection across short courses. Some protocols split dosing morning and evening; others use single daily administration.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Typical protocols run 10–20 day courses repeated every 3–6 months — directly inherited from Khavinson's published Epithalon recommendations rather than derived from independent study of the amidate form.
Protocol Notes
The peptide is sold as a lyophilized powder requiring reconstitution in bacteriostatic water. Subcutaneous injection into abdominal fat is the most commonly described route. Refrigerate after reconstitution. Western clinicians do not prescribe this peptide and there is no anchored clinical protocol; protocols circulate through forum culture and research-chemical vendor literature. The presumed pharmacokinetic advantage over plain Epithalon — longer half-life, greater tissue exposure — has not been demonstrated in human studies.
Claims for this variant exceed the evidence base, which is essentially extrapolation from plain Epithalon plus chemistry-based reasoning about peptidase resistance. Not FDA-approved. Russian Khavinson protocols come from a single-lab tradition that has not been independently replicated in Western laboratories. Research-chemical supply is not authorized for human use.
Timeline of Effects
Onset
Not characterized in controlled studies. Subjective sleep effects, when reported by users, are described within the first few days of a course, consistent with the purported pineal/melatonin mechanism. Telomerase activation, if it occurs, would not produce noticeable acute subjective effects.
Peak Effect
Khavinson-style protocols measure outcomes at the end of a 10–20 day course. There is no characterized peak curve for this specific variant; users typically infer it from Epithalon convention.
After Discontinuation
No documented withdrawal or rebound. If the proposed mechanism is correct, structural changes (e.g., telomere length) would persist beyond dosing until counterbalanced by cell division. Subjective effects, when reported, fade within days to weeks of cessation.
Monitoring & Measurement
Bloodwork & Labs
- •No validated biomarker exists for this peptide or its activity
- •Leukocyte telomere length — commercially offered, but with poor reproducibility between labs and methods, and no established relationship to health outcomes at an individual level
- •Standard age-related panels (fasting glucose, HbA1c, lipids, hsCRP) if general healthspan is the goal, since these actually guide action
Functional & Performance Tests
- •Age-appropriate cancer screening, which is the monitoring that genuinely matters here given the telomerase mechanism and the ALT finding in cancer cells
- •Sleep diary or actigraphy if the pineal and melatonin claims are the reason for use
When to Test
Baseline before starting anything, with cancer screening following standard age and risk-based schedules rather than any peptide-driven interval.
Interpretation & Notes
The honest framing is that there is nothing specific to measure. No assay exists for this peptide, no therapeutic range has been defined, and no biomarker has been shown to track its effect in a person. Commercial telomere-length testing deserves particular scepticism as a way to evaluate this compound. Measurement variability between laboratories and methods is substantial, individual telomere length is a weak predictor of anything actionable, and — the point most relevant here — longer telomeres are not straightforwardly good. The FDA's 2026 review states the concern directly: epitalon 'has the potential to be carcinogenic' because it 'has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer'. A test that showed telomere lengthening would not, on current understanding, be unambiguous good news. The monitoring that actually matters for anyone using a telomerase-activating compound is keeping up with age-appropriate cancer screening.
Common Questions
How does this differ from regular Epithalon?
The N-acetyl and amide modifications protect the peptide from enzymatic degradation at both ends, potentially making it more potent and longer-lasting than standard Epithalon. The core tetrapeptide sequence (AEDG) and mechanism remain the same.
What is the relationship between Epithalon and the pineal gland?
Epithalon is a synthetic version of a peptide naturally found in the pineal gland's polypeptide complex. Research shows it can regulate melatonin synthesis in pinealocytes and help normalize the daily melatonin rhythm that declines with aging.
Does Epithalon have epigenetic effects?
Yes, research suggests Epithalon acts as an epigenetic regulator, stimulating gene expression and protein synthesis. Studies show it can modify chromatin structure and influence hTERT gene expression to activate telomerase.
Is telomerase activation a cancer risk?
It is a serious theoretical concern. Telomerase reactivation is one of the mechanisms cancer cells use to achieve replicative immortality, and chronic telomerase upregulation in humans has no long-term safety data. The amidate variant has no dedicated pharmacovigilance program, and even the parent Epithalon literature does not adequately resolve this question. Anyone with active or recent-history malignancy should treat this as a contraindication rather than a manageable risk.
How strong is the evidence specifically for the amidate variant?
Essentially nonexistent as an independent body of work. There is no published head-to-head pharmacokinetic or clinical study comparing N-Acetyl Epithalon Amidate to plain Epithalon, and the variant has no preclinical or human trial program of its own. All claims are extrapolated from the Epithalon literature plus peptide-chemistry reasoning about peptidase resistance from the N-acetyl and C-amide modifications.
Why is most of the research from one Russian lab?
The Epithalon lineage traces almost entirely to Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, dating from the 1980s. Independent Western replication of the lifespan-extension and elderly-cohort findings has been limited, and core in vivo claims have not been reproduced under modern Western trial methodology. In vitro telomerase activation has been observed in some independent settings, but the broader clinical claims rest on a single research tradition.
Who N-Acetyl Epithalon Amidate Is NOT For
- •Active or recent-history cancer — this is no longer only a theoretical concern. The 2025 Brunel replication found that Epitalon lengthened telomeres in breast cancer cell lines through alternative lengthening of telomeres activation, an effect the authors reported was specific to the cancer cells rather than the normal ones. The FDA's own 2026 review states that 'epitalon has the potential to be carcinogenic' on the grounds that it 'has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer', and notes that it did not identify any 2-year carcinogenicity studies for the compound.
- •Pregnancy — no reproductive toxicology of adequate quality; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Pediatric use — no safety or developmental data.
- •Known hypersensitivity to synthetic peptides or to excipients used in research-chemical preparations.
- •Compromised skin integrity at injection site or known infection — research-chemical supply quality and unknown sterility raise infection-risk concerns absent from clinic-supplied medication.
Drug & Supplement Interactions
No clinical drug interaction data exists for this variant specifically. The interaction concerns inherited from Epithalon are theoretical and mechanism-based: concurrent use with anti-cancer chemotherapy or radiation would be mechanistically opposed if the telomerase-activation claim is correct, and co-administration during active oncology treatment is not advised. No CYP-mediated pharmacokinetic interactions are established. Patients on hormonal therapies, immunosuppressants, or oncology-related treatments should disclose use to their prescribing clinician. Combining with other Khavinson bioregulators or longevity-stack peptides is common in forum culture but has not been formally studied for interaction safety.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human data
- • Theoretical concerns about telomerase activation in cancer cells
What We Don't Know
Safety data specific to the N-acetyl amidate form is essentially nonexistent. Extrapolated from Epithalon data. Long-term effects of chronic telomerase activation in humans remain unstudied.
Legal Status
United States
Not FDA-approved for any indication and not a recognised dietary supplement ingredient. The parent compound's regulatory position is more specific than this page previously conveyed, and it has moved recently. Epitalon appears on the FDA's list of bulk drug substances that may present significant safety risks, under the heading of substances nominated for compounding and then withdrawn, with the agency stating that compounded drugs containing it 'may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities' and that it 'lacks sufficient information to know whether the drug would cause harm if administered to humans'. In 2026 the FDA evaluated epitalon free base and epitalon acetate for the 503A Bulks List at its own discretion, for a proposed use in insomnia, and published a briefing document ahead of a July 2026 Pharmacy Compounding Advisory Committee meeting. Its recommendation was negative: 'a balancing of the criteria weighs against epitalon (free base) or epitalon acetate being placed on that list'. The agency found epitalon not well characterised chemically, concluded 'there is a lack of evidence to support the effectiveness' for the proposed use, and noted there are no clinical data supporting safety in humans. The matter proceeds by notice-and-comment rulemaking, so no final listing decision applies today. The acetylated amidated variant has never been nominated and does not appear anywhere in these proceedings.
International
Not approved as a medicine in any Western jurisdiction. The FDA's 2026 review enumerated this precisely, finding epitalon unrecognised in the European and Japanese pharmacopoeias and finding no approved products in Canada, Australia, the United Kingdom, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and none authorised by the EMA. One regulatory event is worth recording because it is often cited loosely: epitalon received an EU orphan drug designation for retinitis pigmentosa on 2 September 2010, and that designation was withdrawn or revoked on 6 January 2016. An orphan designation is an incentive status rather than an efficacy finding, and this one no longer stands. Russia is conspicuously absent from the FDA's list of jurisdictions checked, and this page makes no positive claim about Russian status in either direction — the registered article in that tradition is epithalamin, the pineal extract, rather than the synthetic tetrapeptide. No registration of the acetylated amidated variant was identified in any public regulatory database anywhere.
Sports & Competition
Not named anywhere on the WADA 2027 Prohibited List — a text search of the published list returns no occurrence of epitalon, epithalon or AEDG. S0 applies and the wording fits unusually well: it covers 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use', naming 'peptides' explicitly among its examples. Neither the parent nor this variant has such approval, so both are prohibited at all times. S0 substances are Specified Substances, which affects sanction length but not whether a violation is found.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
The amidate version is proven to work better than regular Epithalon.
Reality
There is no published head-to-head clinical or pharmacokinetic study demonstrating superiority. The structural modifications are reasonable from a peptide-chemistry standpoint, but the inferred clinical benefit is extrapolation, not data. Marketing claims of enhanced potency or duration are not anchored to comparative human evidence.
Myth
Russian approval or registration means this peptide is safe and effective.
Reality
The amidate variant is not a registered pharmaceutical even in Russia. The broader Khavinson peptide bioregulator ecosystem includes dietary-supplement-style products and investigational protocols, but registration in that framework is not equivalent to Western drug approval, and approval anywhere does not equal independent safety and efficacy validation.
Myth
Vladimir Khavinson won the Nobel Prize for his work on peptide bioregulators.
Reality
He did not. Khavinson's group has published extensively, but the body of work has not been recognized at that level by the broader scientific community, and core claims have not been independently replicated in Western laboratories. Persistent online attributions to a Nobel Prize are inaccurate.
Myth
Because it is just four amino acids with simple modifications, it is inherently safe.
Reality
Small molecular size does not imply safety. If the claimed mechanism is real, the peptide is modulating cell-cycle and senescence biology — exactly the biology where cancer and tissue-dysregulation safety concerns arise. Safety has to be established by data, not inferred from molecular weight.
Myth
Independent Western research has confirmed Epithalon and its variants extend lifespan.
Reality
Very little. The lifespan literature concentrates in the Khavinson research program. In vitro telomerase activation has been reported in some independent settings, but in vivo lifespan extension claims and Russian elderly-cohort findings have not been replicated in Western laboratories under modern trial-methodology standards.
Published Research
28 studiesEpitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.
Jain et al. (Int J Mol Sci 2026) — an independent US review, declaring that no author has a financial interest in epitalon or epithalamin, and the most useful external appraisal available. It separates epitalon from epithalamin, which are routinely conflated, assesses the literature by whether findings have been independently replicated, and states that no adequately powered randomised trial has established therapeutic efficacy.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.
The November 2025 correction to the Brunel telomerase paper, replacing the figures in the telomere-length, hTERT-expression and telomerase-activity panels. The conclusions were not retracted and the paper stands, but anyone relying on its quantitative results should be reading the corrected version.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
Al-Dulaimi et al. (Biogerontology 2025) — the independent replication the Epitalon literature had lacked for 22 years, from Brunel University London with no Khavinson involvement and no declared competing interests. Dose-dependent telomere lengthening in normal epithelial and fibroblast cells through hTERT and telomerase upregulation. The finding that should temper enthusiasm is in the cancer arm: in breast cancer lines 21NT and BT474, telomeres lengthened through alternative lengthening of telomeres activation, which the authors found was specific to the cancer cells. Note that this paper carries a published correction — the figures in its telomere-length, hTERT and telomerase panels were wrong in the original and were replaced.
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy
Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties
Epitalon-activated telomerase enhances bovine oocyte maturation rate and post-thawed embryo development
Epigenetic Modification Under the Influence of Peptide Bioregulators on the 'Old' Chromatin
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes.
Effect of short peptides on neuronal differentiation of stem cells
Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland
Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations.
Vanhee et al. (Drug Test Anal 2015) — a Belgian public-health laboratory identifying epitalon in two illegal pharmaceutical preparations. Concrete evidence for what this page says about supply channels, rather than the usual inference from an unregulated market.
Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture
Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice.
Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas
Peptide promotes overcoming of the division limit in human somatic cell
Effect of regulatory peptides on gene transcription
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice
Anisimov et al. (Biogerontology 2003) — the most-cited lifespan result, in female SHR mice, covering ageing biomarkers, life span and spontaneous tumour incidence. Khavinson is the second author, so this is originating-group work rather than independent confirmation; a decade of similar rodent lifespan studies from the same collaboration followed.
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
Khavinson, Bondarev and Butyugov (Bull Exp Biol Med 2003) — the origin of the telomerase claim that sells this entire peptide family. Epithalon added to telomerase-negative human fetal fibroblast culture induced expression of the catalytic subunit, telomerase activity and telomere elongation. Three authors, one institute, a low-impact journal, and no independent replication for the next 22 years.
Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats.
Djeridane et al. (J Endocrinol Invest 2003) — the negative result the melatonin claim needs to be read against, and it carries unusual weight because Khavinson and Anisimov are co-authors on it. In perifused pineal glands from young and old rats, AEDG at 10⁻⁴ to 10⁻⁶ M 'had no significant effect upon melatonin secretion whatever the age of the animals', and did not modify isoproterenol-stimulated melatonin either. The authors conclude the tetrapeptide 'does not seem to play a role, at least in vitro, in the control of melatonin secretion by the rat pineal gland'.
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
Khavinson et al. (Neuro Endocrinol Lett 2002) — the single human study underpinning the retinitis pigmentosa claim, and it is thinner than its PubMed 'Controlled Clinical Trial' tag suggests. The paper is largely a Campbell rat study, and its human content amounts to a statement that epitalon therapy in patients with degenerative retinal lesions produced a positive clinical effect in 90% of cases, with no sample size, control arm, randomisation or blinding described. Originating group.
Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice.
FDA briefing document: Epitalon (free base) and epitalon acetate for the 503A Bulk Drug Substances List
FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 28PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.